0001104659-23-040848.txt : 20230403 0001104659-23-040848.hdr.sgml : 20230403 20230403161514 ACCESSION NUMBER: 0001104659-23-040848 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230331 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230403 DATE AS OF CHANGE: 20230403 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Liquidia Corp CENTRAL INDEX KEY: 0001819576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851710962 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39724 FILM NUMBER: 23792785 BUSINESS ADDRESS: STREET 1: 419 DAVIS DRIVE, SUITE 100 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919.328.4400 MAIL ADDRESS: STREET 1: 419 DAVIS DRIVE, SUITE 100 CITY: MORRISVILLE STATE: NC ZIP: 27560 8-K 1 tm2311372d1_8k.htm FORM 8-K
0001819576 false 0001819576 2023-03-31 2023-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 31, 2023

 

LIQUIDIA CORPORATION
(Exact name of registrant as specified in its charter)
     
Delaware 001-39724 85-1710962

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

     
419 Davis Drive, Suite 100, Morrisville, North Carolina 27560
(Address of principal executive offices) (Zip Code)

  

Registrant’s telephone number, including area code: (919) 328-4400

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock LQDA The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

 

Item 1.01 Entry Into a Material Definitive Agreement.

 

On March 31, 2023, Liquidia Corporation, a Delaware corporation (the “Company”) through Liquidia Technologies, Inc., a Delaware corporation (“Liquidia Technologies”) and wholly owned subsidiary of the Company, entered into a Research License Agreement (the “Agreement”) with Glaxo Group Limited, a company organized and existing under the laws of England (“GSK”). The Agreement supersedes and replaces that certain Inhalation Collaboration and Option Agreement, dated as of June 15, 2012, by and between Liquidia Technologies and GSK, as amended on May 13, 2015, November 19, 2015 and June 24, 2019 (the “Prior Agreement”).

 

Pursuant to the terms of the Agreement, the Company has granted to GSK a non-exclusive, non-sublicensable (except to affiliates), royalty free license to use the Company’s proprietary PRINT® technology for the sole purpose of conducting pre-clinical research and pre-clinical development of inhaled formulations of GSK’s Molecules (as defined in the Agreement) in the Field (as defined in the agreement) and in the Territory (as defined in the Agreement). Subject to the terms and conditions of the Agreement, the Company and GSK will own and retain all rights, title, and interest in and to all inventions, discoveries and other subject matter (including Know-How (as defined in the Agreement)) together with all intellectual property rights therein which are owned or controlled by such party as of the date of the Agreement or which are invented or acquired by or on behalf of such party independent of the Agreement.

 

The Agreement is effective upon signing. Unless earlier terminated, the Agreement will continue in effect until the later of (i) the expiration of the last-to-expire Valid Claim (as defined in the Agreement) included within the Liquidia Technology (as defined in the Agreement) and (ii) all Arising PRINT Improvements (as defined in the Agreement) and Liquidia Know-How (as defined in the Agreement) are in the public domain. GSK may terminate the Agreement upon at least thirty (30) days’ prior written notice to the Company. The Agreement may also be terminated by either party for a material breach by the other party, subject to notice and cure provisions, or in the event of the other party’s insolvency. In the Agreement, each party made customary representations and warranties and agreed to customary covenants, including, without limitation, with respect to indemnification, for transactions of this type.

 

The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which will be filed as an exhibit to the Company’s next Quarterly Report on Form 10-Q.

 

Item 1.02 Termination of a Material Definitive Agreement.

 

The information provided in Item 1.01 of this Current Report on Form 8-K regarding the termination of the Prior Agreement is incorporated by reference into this Item 1.02.

 

Item 8.01 Other Events.

 

On April 3, 2023, the Company issued a press release announcing its entrance into the Agreement with GSK. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference into this Item 8.01.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)

 

Exhibit
No.		   Exhibit
99.1   Press Release of Liquidia Corporation, dated April 3, 2023.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

April 3, 2023 Liquidia Corporation
   
  By: /s/ Michael Kaseta
    Name: Michael Kaseta
    Title: Chief Financial Officer

 

 

 EX-99.1 2 tm2311372d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

Logo, company name Description automatically generated

 

Liquidia and GSK Restructure License to PRINT Technology for Inhaled Applications

 

-New agreement supersedes the collaboration agreement entered in 2012

-GSK retains non-exclusive right to use PRINT for pre-clinical research for inhaled delivery

-Liquidia can apply PRINT to any inhaled application other than identified GSK proprietary molecules

 

MORRISVILLE, N.C., April 3, 2023 - Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that it has entered a new, non-exclusive license agreement with GSK to enable pre-clinical research of inhaled formulations of GSK’s molecules based upon Liquidia’s proprietary PRINT® technology. This agreement supersedes the collaboration agreement between the parties from 2012. Liquidia now will have the right to apply PRINT to all inhaled formulations other than certain identified GSK proprietary molecules. GSK will retain a non-exclusive, non-sublicensable, royalty-free license for the sole purpose of conducting pre-clinical research and pre-clinical development.

 

Roger Jeffs, Chief Executive Officer of Liquidia, stated: “We are very happy to have re-structured our relationship with GSK to enable both parties to maximize the proven benefits of PRINT technology for inhaled delivery. As demonstrated by YUTREPIA™, the ability to precisely engineer uniform particles for inhalation can enhance patient benefits. This agreement will enable Liquidia to develop more products and collaborations that leverage the proprietary benefits of PRINT to deliver high-value, inhaled medicines. At the same time, GSK will be able to explore the use of PRINT for potential new therapies.”

 

As background, Liquidia and GSK entered a collaboration in June 2012 to research applications of PRINT technology to inhaled therapies. After the exercise of GSK’s option under the collaboration agreement in September 2015, it had a worldwide license to certain intellectual property related to PRINT that was exclusive in the field of inhaled therapeutics other than inhaled treprostinil. Under the terms of the new agreement, GSK will be required to seek an expanded license before it may use PRINT for clinical or commercial purposes.

 

About YUTREPIA™ (treprostinil) inhalation powder

 

YUTREPIA is an investigational, inhaled dry powder formulation of treprostinil delivered through a proven, convenient, palm-sized device. On November 5, 2021, the U.S. Food and Drug Administration (FDA) issued a tentative approval for YUTREPIA, which is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in adult patients with New York Heart Association (NYHA) Functional Class II-III symptoms. The FDA has confirmed that YUTREPIA may add the indication to treat pulmonary hypertension with interstitial lung disease (PH-ILD) without additional clinical studies. YUTREPIA was designed using Liquidia’s PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape, and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. Liquidia has completed INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, an open-label, multi-center phase 3 clinical study of YUTREPIA in patients diagnosed with PAH who are naïve to inhaled treprostinil or who are transitioning from Tyvaso® (nebulized treprostinil). YUTREPIA was previously referred to as LIQ861 in investigational studies.

 

Tyvaso® is a registered trademarks of United Therapeutics Corporation.

 

 

 

 

About Liquidia Corporation

 

Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.

 

Cautionary Statements Regarding Forward-Looking Statements

 

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related submission contents and timelines, including the potential for final FDA approval of the NDA for YUTREPIA and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the SEC, including the impact of the coronavirus (COVID-19) outbreak on our Company and our financial condition and results of operations, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact Information

 

Media & Investors:
Jason Adair
Senior Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com

 

 

 

 EX-101.SCH 3 lqda-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 lqda-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 lqda-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2311372d1_ex99-1img01.gif GRAPHIC begin 644 tm2311372d1_ex99-1img01.gif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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Mar. 31, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 31, 2023
Entity File Number 001-39724
Entity Registrant Name LIQUIDIA CORPORATION
Entity Central Index Key 0001819576
Entity Tax Identification Number 85-1710962
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 419 Davis Drive
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Morrisville
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27560
City Area Code 919
Local Phone Number 328-4400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock
Trading Symbol LQDA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
XML 8 tm2311372d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001819576 2023-03-31 2023-03-31 iso4217:USD shares iso4217:USD shares 0001819576 false 8-K 2023-03-31 LIQUIDIA CORPORATION DE 001-39724 85-1710962 419 Davis Drive Suite 100 Morrisville NC 27560 919 328-4400 false false false false Common stock LQDA NASDAQ true true EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://liquidia.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2311372d1_8k.htm lqda-20230331.xsd lqda-20230331_lab.xml lqda-20230331_pre.xml tm2311372d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2311372d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2311372d1_8k.htm" ] }, "labelLink": { "local": [ "lqda-20230331_lab.xml" ] }, "presentationLink": { "local": [ "lqda-20230331_pre.xml" ] }, "schema": { "local": [ "lqda-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "lqda", "nsuri": "http://liquidia.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2311372d1_8k.htm", "contextRef": "From2023-03-31to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://liquidia.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2311372d1_8k.htm", "contextRef": "From2023-03-31to2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://liquidia.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-040848-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-040848-xbrl.zip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